RAC 2.20% $1.78 race oncology ltd

Industry news, page-1492

  1. 146 Posts.
    lightbulb Created with Sketch. 642
    Interestingly, today Reach Pharmaceuticals has announced that the TGA has granted dexrazoxane Orphan Designation in Australia.

    https://hotcopper.com.au/data/attachments/5715/5715422-253d92c6ddba13ef6eecacff56abeacd.jpg
    Reach have 6 months now I believe to submit their registration dossier to the TGA for evaluation.

    Whilst it doesn't have a direct impact on RAC I do find it interesting that the noise around cardio-oncology and cardioprotection is starting to be amplified globally. RAC couldn't be better positioned to become a global leader in this space. Looking forward to seeing how the team plan to execute on cardio-oncology in the new strategy.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.